Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Massengill, Susan
NCT04009668: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Completed	2	7	US	adalimumab, Humira	University of Michigan	FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease	09/23	10/23
NEPTUNE, NCT01209000: Nephrotic Syndrome Study Network	Recruiting	N/A	1200	Canada, US	Kidney Biopsy	University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation	Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental	06/29	06/29
C-PROBE, NCT01016613: Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center	Recruiting	N/A	1800	US		University of Michigan, St. John Health System, Michigan, Temple University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Chronic Kidney Disease, Glomerulopathy	07/30	07/30
Lamothe, Jennifer
NCT04239391: Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)	Recruiting	3	150	US	Triferic, FPC	Rockwell Medical Technologies, Inc.	End Stage Renal Disease	08/23	11/23
NCT04009668: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Completed	2	7	US	adalimumab, Humira	University of Michigan	FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease	09/23	10/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Massengill, Susan
NCT04009668: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Completed	2	7	US	adalimumab, Humira	University of Michigan	FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease	09/23	10/23
NEPTUNE, NCT01209000: Nephrotic Syndrome Study Network	Recruiting	N/A	1200	Canada, US	Kidney Biopsy	University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation	Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental	06/29	06/29
C-PROBE, NCT01016613: Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center	Recruiting	N/A	1800	US		University of Michigan, St. John Health System, Michigan, Temple University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Chronic Kidney Disease, Glomerulopathy	07/30	07/30
Lamothe, Jennifer
NCT04239391: Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)	Recruiting	3	150	US	Triferic, FPC	Rockwell Medical Technologies, Inc.	End Stage Renal Disease	08/23	11/23
NCT04009668: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Completed	2	7	US	adalimumab, Humira	University of Michigan	FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease	09/23	10/23